Editorial Views  |   January 2017
Innovative Disruption in the World of Neuromuscular Blockade: What Is the “State of the Art?”
Author Notes
  • From the Department of General Anesthesia, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio (M.N.); and Department of Anesthesiology, University of Utah, Salt Lake City, Utah (K.B.J.).
  • This article has been selected for the Anesthesiology CME Program. Learning objectives and disclosure and ordering information can be found in the CME section at the front of this issue.
    This article has been selected for the Anesthesiology CME Program. Learning objectives and disclosure and ordering information can be found in the CME section at the front of this issue.×
  • Corresponding article on page 173.
    Corresponding article on page 173.×
  • Accepted for publication May 23, 2016.
    Accepted for publication May 23, 2016.×
  • Address correspondence to Dr. Naguib: naguibm@ccf.org
Article Information
Editorial Views / Neuromuscular Diseases and Drugs / Neurosurgical Anesthesia / Technology / Equipment / Monitoring
Editorial Views   |   January 2017
Innovative Disruption in the World of Neuromuscular Blockade: What Is the “State of the Art?”
Anesthesiology 1 2017, Vol.126, 12-15. doi:10.1097/ALN.0000000000001410
Anesthesiology 1 2017, Vol.126, 12-15. doi:10.1097/ALN.0000000000001410
SUGAMMADEX represents an innovative disruption in drug technology. The recent approval of sugammadex by the Food and Drug Administration provides us with an opportunity to revisit the “state of the art” and emphasize important nuances in the administration, monitoring, and reversal of neuromuscular blockade. To that end, in this issue of Anesthesiology, Brull and Kopman1  review the status of monitoring and reversal of neuromuscular blockade, highlight persistent concerns with residual neuromuscular block, and address approaches on how to minimize them. This editorial highlights a few of the more important clinical implications of this review to include practice considerations of sugammadex versus neostigmine, the importance of monitoring neuromuscular blockade, clinically relevant drug interactions, adverse effects, and the pharmacoeconomics of sugammadex.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large